CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Tribute Pharmaceuticals Canada Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Tribute Pharmaceuticals Canada Inc
151 Steeles Avenue East
Phone: (905) 876-1118p:905 876-1118 Milton, ON  L9T 1Y1  Canada Fax: (519) 434-4382f:519 434-4382
This company was Merged or Acquired on 2/5/2016.
This company ceased filing statements with the SEC on 2/12/2016.
On 2/5/2016, the Company combined with POZEN Inc to create Aralez Pharmaceuticals Inc.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Tribute Pharmaceuticals Canada Inc. is a specialty pharmaceutical company. The Company has a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada. The Company targets several therapeutic areas in Canada with a particular interest in products for the treatment of neurology, pain, urology, dermatology and endocrinology/cardiology. Its current portfolio consists of 13 marketed products in Canada, including NeoVisc (Triple and Single Dose), Uracyst, Bezalip SR, Soriatane, Cambia, Fiorinal, Fiorinal C, Visken, Durela, Proferrin, Resultz, Viskazide and Collatamp G. NeoVisc and Uracyst are also sold in other countries through strategic partners of the Company. It also has an exclusive license for the development and commercialization of Bezalip SR (bezafibrate) for the United States market and an exclusive license for the development and commercialization of bilastine in Canada.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201512/31/2014YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board ArnoldTenney 72 12/1/2011 4/29/2004
President, Chief Executive Officer, Director Robert P.Harris 59 12/1/2011 12/1/2011
Chief Financial Officer, Director ScottLangille 58 1/1/2013 12/1/2011
7 additional Officers and Directors records available in full report.

Business Names
Business Name
Medical Futures Inc.
Stellar International Inc
Stellar International Inc. (USA)
Stellar Pharmaceuticals Inc. (USA)
Tribute Pharmaceuticals International Inc.

General Information
Stock Exchange: CVE
Fax Number: (519) 434-4382


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023